Evidence map›Paper›PMID 40607392›Full record

ArticleFrontiers in immunology2025

AAV-HBV mouse model replicates the intrahepatic immune landscape of chronic HBV patients at single-cell level.

Nádia Conceição-Neto, Wim Pierson, Qinglin Han, Zhiyuan Yao, Qun Wu, Koen Dockx, Liese Aerts, Dries De Maeyer, Matthias Beyens, Koen Van den Berge and 7 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Nádia Conceição-NetoID Discovery, Infectious Diseases Therapeutic Area, Johnson & Johnson Innovative Medicine, Beerse, Belgium.
Wim PiersonID Discovery, Infectious Diseases Therapeutic Area, Johnson & Johnson Innovative Medicine, Beerse, Belgium.
Qinglin HanID Discovery, Infectious Diseases Therapeutic Area, Johnson & Johnson Innovative Medicine, Shanghai, China.
Zhiyuan YaoID Discovery, Infectious Diseases Therapeutic Area, Johnson & Johnson Innovative Medicine, Brisbane, CA, United States.
Qun WuID Discovery, Infectious Diseases Therapeutic Area, Johnson & Johnson Innovative Medicine, Shanghai, China.
Koen DockxCharles River Laboratories, Beerse, Belgium.
Liese AertsID Discovery, Infectious Diseases Therapeutic Area, Johnson & Johnson Innovative Medicine, Beerse, Belgium.
Dries De MaeyerDiscovery Therapeutics and Molecular Pharmacology, Johnson & Johnson Innovative Medicine, Beerse, Belgium.
Matthias BeyensDiscovery Therapeutics and Molecular Pharmacology, Johnson & Johnson Innovative Medicine, Beerse, Belgium.
Koen Van den BergeStatistics and Decision Sciences, Johnson & Johnson Innovative Medicine, Beerse, Belgium.
Chris LiID Discovery, Infectious Diseases Therapeutic Area, Johnson & Johnson Innovative Medicine, Brisbane, CA, United States.
George KukoljID Discovery, Infectious Diseases Therapeutic Area, Johnson & Johnson Innovative Medicine, Brisbane, CA, United States.
Ren ZhuID Discovery, Infectious Diseases Therapeutic Area, Johnson & Johnson Innovative Medicine, Shanghai, China.
Vinod KrishnaID Discovery, Infectious Diseases Therapeutic Area, Johnson & Johnson Innovative Medicine, Spring House, PA, United States.
Ondřej PodlahaID Discovery, Infectious Diseases Therapeutic Area, Johnson & Johnson Innovative Medicine, Brisbane, CA, United States.
Isabel NájeraID Discovery, Infectious Diseases Therapeutic Area, Johnson & Johnson Innovative Medicine, Brisbane, CA, United States.
Ellen Van GulckID Discovery, Infectious Diseases Therapeutic Area, Johnson & Johnson Innovative Medicine, Beerse, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Unresolved hepatitis B virus (HBV) infection leads to a progressive state of HBV-specific immune dysfunctionality that characterizes chronic infection. The immune-competent adeno associated virus (AAV)-HBV mouse model is commonly used preclinically, though a comprehensive characterization of the liver immune microenvironment and its translatability to human infection is still lacking. We investigated the intrahepatic immune profile of the AAV-HBV mouse model at a single-cell level and compared with data from CHB patients in immune tolerant (IT) and immune active (IA) clinical stages. Methods: Immune exhaustion was profiled through an iterative subclustering approach for cell-typing analyses of single-cell RNA-sequencing data in CHB donors and compared to the AAV-HBV mouse model 4-weeks and 24-weeks post-transduction to assess its translatability. This was confirmed using an exhaustion flow cytometry panel at 4 and 42-weeks post-transduction. Results: Using single-cell RNA-sequencing, CD8 pre-exhausted T-cells with self-renewing capacity ( Discussion: Long term high titer AAV-HBV mouse liver transduction led to T-cell exhaustion, as evidenced by expression of conventional immune checkpoint markers at mRNA and protein levels. In both IT and IA donors, a similar CD8 exhausted T-cell population was identified, with increased frequency observed in IA donors. These data support the use of the AAV-HBV mouse model to study classical T-cell exhaustion in HBV infection and the effect of immune-based therapeutic interventions.

Indexed as

CD8-Positive T-LymphocytesDependovirusHepatitis B, ChronicHepatitis B virusLiverAnimalsDisease Models, AnimalFemaleHumansMaleMiceSingle-Cell AnalysisAAV-HBV-infected mouse modelchronic HBVhepatitis B virussingle-cell transcriptomeT cell exhaustion

Identifiers

PMID40607392
PMCPMC12214900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.